Overview

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

Status:
Not yet recruiting
Trial end date:
2025-10-09
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals